Table 1.
Demographic and transplant-related clinical data
| Patient No. (Age, yr/Sex) | Initial Cause of Kidney Failure | Transplant Donor Type | Transplant Vintage, mo | Prior Rejection History | Indication for Study Biopsy | Clinical Diagnosis at Time of Biopsy (Treatment) |
|---|---|---|---|---|---|---|
| 1 (51/M) | PCKD | Living | 25 | No | Research protocol | No significant pathology |
| 2 (60/M) | PCKD | Deceased | 24 | No | Research protocol | No significant pathology |
| 3 (68/M) | Diabetes type 2 | Deceased | 55 | No | Allograft dysfunction | Transplant glomerulopathy (rituximab) |
| 4 (57/M) | Pyelo/interstitial nephritis | Living | 17 | No | Research protocol | Mild tubulitis and interstitial infiltrate (no treatment) |
| 5 (64/W) | Lupus nephritis | Living | 148 | Acute cellular rejection (6.2 yr prestudy) | Allograft dysfunction | Recurrent mesangial lupus nephritis (prednisone pulse) |
| 6 (55/M) | IgA nephropathy | Living | 105 | No | Allograft dysfunction | Interstitial fibrosis and tubular atrophy with significant interstitial inflammation (MMF dose increased, angiotensin receptor blocker initiated) |
| 7 (51/M) | PCKD | Deceased | 24 | No | Research protocol | Borderline acute cellular rejection (prednisone pulse) |
| 8 (37/M) | Obstructive uropathy | Living | 24 | Borderline acute cellular rejection (1.7 yr prestudy) | Research protocol | IgA nephropathy (prednisone pulse) |
| 9 (53/M) | IgA nephropathy | Living | 120 | No | Allograft dysfunction | IgA nephropathy (no treatment) |
| 10 (43/M) | Henoch–Schonlein purpura | Living | 39 | Borderline acute cellular rejection (3.2 yr prestudy) | Allograft dysfunction | Borderline acute cellular rejection superimposed on transplant glomerulopathy (prednisone pulse, rituximab infusions) |
| 11 (48/M) | Membranous nephropathy | Deceased | 24 | No | Research protocol | Membranous nephropathy (angiotensin receptor blocker) |
| 12 (67/W) | Diabetes type 2 | Deceased | 43 | No | Allograft dysfunction | Transplant glomerulopathy (increase angiotensin receptor blocker dose) |
| 13 (46/W) | Lupus nephritis | Living | 37 | No | Allograft dysfunction | Banff grade 1B acute cellular rejection (solumedrol pulse with tapering prednisone) |
| 14 (51/M) | IgA nephropathy | Living | 108 | No | Allograft dysfunction | Interstitial fibrosis and tubular atrophy (no treatment) |
| 15 (66/M) | IgA nephropathy | Deceased | 70 | No | Allograft dysfunction | Acute antibody-mediated rejection (solumedrol pulse with tapering prednisone, intravenous Ig) |
| 16 (50/W) | Lupus nephritis | Living | 45 | No | Allograft dysfunction | Class 3 lupus nephritis (dolumedrol pulse and increase MMF dose) |
M, man; PCKD, polycystic kidney disease; W, woman; MMF, mycophenolate mofetil.